Return On Equity
316%
Trailing 12 months · Through 30 Sep 2025
YoY relative change: -63%
Zivo Bioscience, Inc. financial metrics
Period Q3 2025 · Filed 14 Nov 2025
Key metrics snapshot
Return On Assets
-1002%
Third-party reference; reporting period not verified
Operating Margin
-1552%
Third-party reference; reporting period not verified
Current Ratio
0.08x
Third-party reference; reporting period not verified
Quick Ratio
0.02x
Third-party reference; reporting period not verified
Debt-to-equity
-1.53x
Period-end balance · Through 30 Sep 2025
YoY relative change: +20%
Revenues YoY
165%
Trailing 12 months · Through 30 Sep 2025
NetIncomeLoss YoY
38%
Trailing 12 months · Through 30 Sep 2025
Profitability
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
316%
Trailing 12 months · 30 Sep 2025
|
-63% |
| Return On Assets |
-1002%
Third-party reference; reporting period not verified
|
|
| Operating Margin |
-1552%
Third-party reference; reporting period not verified
|
Financial Health
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.08x
Third-party reference; reporting period not verified
|
|
| Quick Ratio |
0.02x
Third-party reference; reporting period not verified
|
|
| Debt-to-equity |
-1.53x
Period-end balance · 30 Sep 2025
|
+20% |
Growth
| Metric | Latest value | YoY relative change |
|---|---|---|
| Revenues YoY |
165%
Trailing 12 months · 30 Sep 2025
|
|
| NetIncomeLoss YoY |
38%
Trailing 12 months · 30 Sep 2025
|
Share Metrics
| Metric | Latest value | YoY relative change |
|---|---|---|
| Entity Common Stock, Shares Outstanding |
3,888,595
Period-end balance · 09 Nov 2025
|
+9.7% |
| Common Stock, Shares, Outstanding |
3,832,327
Period-end balance · 30 Sep 2025
|
+9.8% |
| Common Stock, Value, Issued |
$3,832
Period-end balance · 30 Sep 2025
|
+9.8% |
| Weighted Average Number of Shares Outstanding, Diluted |
3,817,172
Reported period · 30 Sep 2025
|
+12% |
Supporting Metrics
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Accounts Payable, Current |
$992,990
Period-end balance · 30 Sep 2025
|
+26% |
| Accrued Liabilities, Current |
$1,613,940
Period-end balance · 30 Sep 2025
|
+43% |
| Additional Paid in Capital |
$140,560,590
Period-end balance · 30 Sep 2025
|
+5.5% |
| Assets |
$559,452
Period-end balance · 30 Sep 2025
|
+13% |
| Assets, Current |
$281,399
Period-end balance · 30 Sep 2025
|
-36% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$57,222
Period-end balance · 30 Sep 2025
|
-64% |
| Common Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2025
|
0% |
| Common Stock, Shares Authorized |
25,000,000
Period-end balance · 30 Sep 2025
|
0% |
| Common Stock, Shares, Issued |
3,832,327
Period-end balance · 30 Sep 2025
|
|
| Earnings Per Share, Diluted |
-2
Trailing 12 months · 30 Sep 2025
|
+60% |
| General and Administrative Expense |
$4,826,813
Trailing 12 months · 30 Sep 2025
|
-54% |
| Interest Expense |
$12,959
Reported period · 30 Sep 2025
|
+51% |
| Lessee, Operating Lease, Liability, to be Paid |
$354,871
Period-end balance · 30 Sep 2025
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Four |
$62,747
Period-end balance · 30 Sep 2025
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year One |
$94,676
Period-end balance · 30 Sep 2025
|
+1923% |
| Lessee, Operating Lease, Liability, to be Paid, Year Three |
$60,910
Period-end balance · 30 Sep 2025
|
|
| Lessee, Operating Lease, Liability, to be Paid, Year Two |
$97,695
Period-end balance · 30 Sep 2025
|
|
| Lessee, Operating Lease, Liability, Undiscounted Excess Amount |
$69,034
Period-end balance · 30 Sep 2025
|
|
| Liabilities |
$3,846,055
Period-end balance · 30 Sep 2025
|
+49% |
| Liabilities and Equity |
$559,452
Period-end balance · 30 Sep 2025
|
+13% |
| Liabilities, Current |
$3,614,268
Period-end balance · 30 Sep 2025
|
+40% |
| Operating Income (Loss) |
-$8,456,422
Trailing 12 months · 30 Sep 2025
|
+38% |
| Operating Lease, Liability |
$285,837
Period-end balance · 30 Sep 2025
|
|
| Operating Lease, Liability, Current |
$65,713
Period-end balance · 30 Sep 2025
|
+198% |
| Operating Lease, Liability, Noncurrent |
$220,124
Period-end balance · 30 Sep 2025
|
|
| Operating Lease, Right-of-Use Asset |
$270,373
Period-end balance · 30 Sep 2025
|
+1112% |
| Operating Lease, Weighted Average Discount Rate, Percent |
0.11
Period-end balance · 30 Sep 2025
|
|
| Research and Development Expense |
$3,695,819
Trailing 12 months · 30 Sep 2025
|
+15% |
| Retained Earnings (Accumulated Deficit) |
-$143,851,025
Period-end balance · 30 Sep 2025
|
-6.3% |
| Revenue from Contract with Customer, Excluding Assessed Tax |
$209,025
Trailing 12 months · 30 Sep 2025
|
+165% |
| Stockholders' Equity Attributable to Parent |
-$3,286,603
Period-end balance · 30 Sep 2025
|
-58% |
Comparisons, sources and research notes
Sources and sharing
ZIVO - Zivo Bioscience, Inc. Financial Facts
- Context
- Latest metrics period: Q3 2025
- Latest reported value
- Return On Equity 316%
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Tracking and update notes
Why revisit this company facts page
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
- Latest source-backed update
- Latest metrics period Q3 2025
- Why come back
- Use the next filing cycle to compare new facts against this baseline and then verify the detailed metric history.
- Current latest metrics period: Q3 2025.
- Most recent SEC facts end date on this page: 09 Nov 2025.
- Save this filer to return when the next filing-backed metric period changes the picture.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest update for ZIVO - Zivo Bioscience, Inc.
Latest financial period: Q3 2025. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
14 Nov 2025
Page type
Company facts
Latest period
Q3 2025
SEC-backed company facts were refreshed from filings filed on 14 Nov 2025.
Benchmark Context
How Return On Equity compares
Return On Equity is down about 63% versus the comparable prior period.
Compared with
Compared with Zivo Bioscience, Inc.'s recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
- Latest comparable period on this page: Q3 2025.
- Peer context will appear when enough companies report a comparable value for this metric.
- Open the metric history first if you want to verify the exact period-to-period change.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
How to read key metrics on this page
These short guides explain what the headline metrics mean, what to compare next, and where to open the live SEC-backed example for this company.
Plain-English Guide
How to read Revenue on this page
Revenue is the sales a company reports from customers before most expenses are subtracted.
Why people care
People start here to understand business scale and whether demand is growing before they ask about margins or cash flow.
How to read it
Check the latest reported period first, then compare the same quarter or year against prior periods so seasonality does not distort the story.
Compare next
Compare revenue with gross profit, operating income, and operating cash flow to see whether sales are turning into healthy economics.
Revenue can jump because of acquisitions, pricing changes, or revenue-recognition rules, and reporting periods may differ across companies.
Open a live SEC-backed example
Plain-English Guide
How to read Net Income on this page
Net income is profit after operating costs, interest, taxes, and other non-operating items.
Why people care
It is the bottom-line profit figure many users recognize first, especially when they want to compare earnings with sales or cash flow.
How to read it
Use the same quarter or fiscal year comparison first, then check operating income or cash flow if the bottom line moved sharply.
Compare next
Compare it with operating income, EPS, and operating cash flow to see whether earnings are broad-based or driven by one-off items.
Net income can swing because of tax, financing, or accounting adjustments, so it is often less comparable than core operating metrics.
Open a live SEC-backed example
Filing notes and source
Key facts
- ZIVO - Zivo Bioscience, Inc. financial facts use SEC filings; any third-party reference is labeled separately.
- Latest metrics period on this page: Q3 2025.
- Headline metric: Return On Equity 316%.
Change
- Return On Equity YoY relative change: -63%.
- Most recent SEC facts end date: 09 Nov 2025.
Research use
- This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
- Metric cards link to SEC history; a third-party reference may use a different or unverified reporting period.
Evidence
Based on latest 10-Q/10-K
View source filing
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2025-11-09) highlights Return On Equity 316.1%, Return On Assets -1001.9%, and Operating Margin -1551.8%.
Valuation Snapshot
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
No market comparison
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
DCF estimate is unavailable because required valuation inputs are missing.
Missing: Free cash flow.
Input periods, units and SEC sources
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
- Operating cash flow: -3,078,926.0 USD · through 2025-09-30 · prior annual + current YTD − prior YTD SEC source SEC source SEC source
- Capital expenditures: 0.0 USD · through 2013-12-31 · reported annual SEC source
- Cash and equivalents: unavailable on a verified comparable basis
- Debt: unavailable on a verified comparable basis
Data confidence notes
- Free cash flow unavailable: matching usd annual or trailing-12-month operating cash flow and cash capex are required
- Cash and equivalents unavailable: no usd cash balance at the latest balance date
- Debt unavailable: no complete usd debt balance at the latest balance date
- Valuation unavailable: free cash flow is missing
Compare This Company Through SEC-backed Metrics
Use these links to compare ZIVO - Zivo Bioscience, Inc. against other SEC filers on the same metric, then verify the company history from the paired facts page.
Revenues YoY
Latest value: 165%
NetIncomeLoss YoY
Latest value: 38%
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
45.1/100
Caution Confidence high
Return On Equity
316%
Metric score 100.0/100
Return On Assets
-1002%
Metric score 0.0/100
Financial Health
- Current Ratio
- 0.08x
- Quick Ratio
- 0.02x
- Debt to Equity
- -1.53x
Strengths
Return On Equity, Revenues YoY, and NetIncomeLoss YoY
Watchpoints
Return On Assets, Operating Margin, and Current Ratio
Calculation methodology and other links
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- Operating Income / Revenues using matching TTM or quarter periods; basis shown per metric
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- Revenues YoY using available TTM or quarter comparison; basis shown per metric
- Net Income YoY using available TTM or quarter comparison; basis shown per metric
CIK / security context first